The Best Regulatory Intelligence Software for Pharma in 2026
You already have access to lots of reg-intel software. So why are you stuck researching manually every time a client team asks you a question?
The software was built for a different job
If you're at an established pharma, you're covered. There's a Cortellis or IQVIA subscription, a Pink Sheet login, a SharePoint of tracked changes, and regional teams watching their own authorities. Adding another tool to that stack is a hard sell, and it should be.
Most reg-intel groups run like a help desk. A clinical team asks whether FDA has ever accepted a surrogate endpoint in their population. A CMC team asks what stability package cleared review for a product like theirs. The stack you own was built for monitoring and requirements tracking, and neither answers that kind of ask. So it's you, Drugs@FDA's search box, and a stack of 500-page PDFs, keyword-guessing your way to precedent. That's the most expensive way in your company to answer a question.
To be fair to the incumbents: on breadth of markets, they win. Cortellis publishes 80+ markets, IQVIA Reg Intel 110+ countries and regions. If your job is knowing the current requirement in every country you file into, that's what they're for. What they don't have is depth. The documents that answer those asks — SBOAs, discipline reviews, trial protocols, the literature reviewers actually cited — aren't in a requirements catalog.
Two more things we see constantly. The subscription nominally covers a department, but in practice two or three people have logins and everyone else asks them. And any new tool has to get through IT, procurement, and a security review before it answers a single question. We ranked with that in mind.
Methodology & scoring
Facts are from public materials as of August 2026, plus what buyers at large companies tell us directly. We didn't rank consultants here. At pharma scale that's a different budget.
- Does the research for you — or does it hand you a search box
- Traceability — does a claim open to the exact page or passage
- Market reach — how many countries and regions it covers
- Depth per market — review packages, protocols, literature: the documents underneath the rule
- Fits your stack — does it coexist, or demand a migration
- Price transparency
The incumbents beat us on market reach. We beat them on depth. They're different products, and most global teams need both.
Ranked for large regulatory organizations
Rhizome AI
Best for answering client-team asks with cited precedentRhizome is a focused, AI regulatory coworker. The manual part is the part our agents do: a client team asks what FDA accepted for an endpoint across the last thirty comparable programs, and our agents run the searches and read the primary documents — reviews, approval packages, CRLs, guidances, trial records. Hundreds of sources on a hard question, up to 1,000 citations in one answer, back the same day. Every citation opens to the exact passage, so an SME can check any claim in about a minute.
We designed it to sit beside what you already run. Keep Cortellis for coverage and alerts. Keep the regional teams. Connect Rhizome over MCP to the Copilot or Claude your org already rolled out. Our corpus is >45 million documents across >75 health authority databases in >12 markets (as of August 2026 — this increases all the time), with every scanned page processed, because the review packages that carry the real precedent are mostly image-only PDFs.
And we've been through the IT and procurement reviews of very large pharma. Pricing is published, and there's a free tier, so you can test a real question before anyone talks to procurement.
Cortellis (Clarivate)
Best standing curated coverageThere's a reason Cortellis is in so many buildings. The breadth is real, the alerting works, and one contract covers regulatory plus pipeline, deals, IP, and CMC modules.
The limit is scale and traceability. Clarivate publishes 300k+ source documents and 2,000+ expert summaries, and they now ship an AI assistant that returns cited answers. But 300k documents is a curated slice of the record. And a citation that lands on a document still sends you into a 500-page PDF to hunt for the passage. The manual step survives. This is why buyers who have it tell us the analysis still gets redone in-house. Pricing is a custom quote.
IQVIA Reg Intel
Best requirements library, and the widest market reach on this listThe reach is the pitch: requirements for drugs, biologics, devices, and IVDs across 110+ countries and regions. That's more geographies than anything else here, including us. For tracking the current requirement in every market you file into, it's the right tool.
But it holds the rule, not the evidence. No approval packages, no discipline reviews, no protocols. Once you've found the requirement, you're back to researching how authorities actually applied it to programs like yours. The ask isn't answered, just narrowed.
General AI alone (ChatGPT, Claude, Gemini, Copilot)
Already deployed to everyone, and quietly being used for thisThe most overlooked tool in the stack. Your org rolled ChatGPT or Copilot out to thousands of people, and some of them are asking it regulatory questions today. It's good at drafting, decent at orientation, and free at the margin.
And it will answer instantly. The problem is you can't trust the sources: general models answer from memory plus the open web, where blogs and trade press weigh about as much as the primary record. So the manual work doesn't disappear, it moves to verification. Copilot is a special case: it's grounded in your tenant, so it answers questions about the outside world with your own documents.
The productive move is the one your IT department will also prefer: don't add a fourth AI interface. Connect Rhizome to the assistant you already deployed, over MCP.
In-house AI (internal platform builds)
Real capability, usually the wrong targetLarge pharma can build this. There are platform teams, data engineers, and a mandate. The demo works, and the first version impresses.
Then the maintenance shows up: OCR pipelines for scanned filings, refreshes across dozens of authorities, evals proving the agent didn't quietly answer from memory, citation UX an SME will actually trust. You escape manual research by becoming the maintainer. Our take: build AI where your data is the moat. A model that predicts whether a candidate works is core IP. A search layer over the public record is something you can just buy.